FATE THERAPEUTICS INC Debt Securities, Available-for-sale, Unrealized Loss Position
FATE THERAPEUTICS INC (FATE) had Debt Securities, Available-for-sale, Unrealized Loss Position of $268.11 million as of 2023-09-30, per its 10-Q filed 2023-11-08.
Discontinued › Notes › Investments › Debt and Equity Securities
us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition · last filed 2023-11-08
- 2023-09-30: Debt Securities, Available-for-sale, Unrealized Loss Position $268.11M.
- 2023-06-30: Debt Securities, Available-for-sale, Unrealized Loss Position $266.61M.
- 2023-03-31: Debt Securities, Available-for-sale, Unrealized Loss Position $236.75M.
- 2022-12-31: Debt Securities, Available-for-sale, Unrealized Loss Position $270.97M.
| Period end | Debt Securities, Available-for-sale, Unrealized Loss Position |
|---|---|
| 2023-09-30 | $268.11M 10-Q · filed 2023-11-08 |
| 2023-06-30 | $266.61M 10-Q · filed 2023-08-08 |
| 2023-03-31 | $236.75M 10-Q · filed 2023-05-03 |
| 2022-12-31 | $270.97M 10-Q · filed 2023-11-08 |
| 2022-09-30 | $329.76M 10-Q · filed 2022-11-03 |
| 2022-06-30 | $405.00M 10-Q · filed 2022-08-03 |
| 2022-03-31 | $443.80M 10-Q · filed 2022-05-04 |
| 2021-12-31 | $414.13M 10-K · filed 2023-02-28 |
| 2020-12-31 | $166.92M 10-K · filed 2022-02-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Liminatus Pharma, Inc. (LIMN) | United States | $0.282B | |
| Lexeo Therapeutics, Inc. (LXEO) | United States | $0.278B | -4.19 |
| PALISADE BIO, INC. (PALI) | United States | $0.275B | -11.41 |
| Invivyd, Inc. (IVVD) | United States | $0.270B | -2.42 |
| Inhibikase Therapeutics, Inc. (IKT) | United States | $0.296B | -4.44 |
| X4 Pharmaceuticals, Inc (XFOR) | United States | $0.297B | -4.99 |
| SUTRO BIOPHARMA, INC. (STRO) | United States | $0.260B | -3.05 |
| SAB Biotherapeutics, Inc. (SABS) | United States | $0.306B | -25.49 |
| Century Therapeutics, Inc. (IPSC) | United States | $0.306B | -4.02 |
| Lineage Cell Therapeutics, Inc. (LCTX) | United States | $0.241B | -10.35 |